Psychedelic therapy in depression and substance use disorders DOI Creative Commons
Nur Damla Korkmaz, Uğur Çıkrıkçılı,

Merve Akan

et al.

European Journal of Neuroscience, Journal Year: 2024, Volume and Issue: 60(2), P. 4063 - 4077

Published: May 21, 2024

Abstract Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals different cultures thousands years. Classical psychedelics N,N′‐dimethyltryptamine, psilocybin, mescaline and various lysergamides cause specific alterations perception, emotion cognition by acting through serotonin 5‐HT 2A receptor activation. Lysergic acid diethylamide, first famous breakthrough field, was discovered chance Albert Hoffman Zurich Sandoz laboratory 1943, studies on its psychoactive effects began to take place literature. Studies this area were blocked after legislation controlling use research psychedelic drugs came into force 1967, but since 1990s, it has started be matter scientific curiosity again groups. In particular, with crucial reports psychotherapy‐assisted psilocybin applications life‐threatening cancer‐related anxiety depression, new avenues opened treatment psychiatric diseases such as treatment‐resistant depression substance addictions. An increasing number show that very promising potential neuropsychiatric where desired efficiency cannot achieved conventional methods. context, we discuss therapy, encompassing historical development, therapeutic effects—especially trauma disorders disorders—within framework ethical considerations.

Language: Английский

Psychedelics reopen the social reward learning critical period DOI Creative Commons

Romain Nardou,

Edward J. Sawyer, Young Jun Song

et al.

Nature, Journal Year: 2023, Volume and Issue: 618(7966), P. 790 - 798

Published: June 14, 2023

Abstract Psychedelics are a broad class of drugs defined by their ability to induce an altered state consciousness 1,2 . These have been used for millennia in both spiritual and medicinal contexts, number recent clinical successes spurred renewed interest developing psychedelic therapies 3–9 Nevertheless, unifying mechanism that can account these shared phenomenological therapeutic properties remains unknown. Here we demonstrate mice the reopen social reward learning critical period is property across drugs. Notably, time course reopening proportional duration acute subjective effects reported humans. Furthermore, reinstate adulthood paralleled metaplastic restoration oxytocin-mediated long-term depression nucleus accumbens. Finally, identification differentially expressed genes ‘open state’ versus ‘closed provides evidence reorganization extracellular matrix common downstream underlying drug-mediated reopening. Together results important implications implementation psychedelics practice, as well design novel compounds treatment neuropsychiatric disease.

Language: Английский

Citations

154
Accelerated TMS - moving quickly into the future of depression treatment DOI Creative Commons
Sanne J.H. van Rooij,

Amanda R. Arulpragasam,

William M. McDonald

et al.

Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 49(1), P. 128 - 137

Published: May 22, 2023

Abstract Accelerated TMS is an emerging application of Transcranial Magnetic Stimulation (TMS) aimed to reduce treatment length and improve response time. Extant literature generally shows similar efficacy safety profiles compared the FDA-cleared protocols for treat major depressive disorder (MDD), yet accelerated research remains at a very early stage in development. The few applied have not been standardized vary significantly across set core elements. In this review, we consider nine elements that include parameters (i.e., frequency inter-stimulation interval), cumulative exposure number days, sessions per day, pulses session), individualized target dose), brain state context concurrent treatments). Precisely which these critical what are most optimal MDD unclear. Other important considerations durability effect, as doses increase over time, possibility advantage functional neuronavigation, use biological readouts, accessibility patients need treatment. Overall, appears hold promise time achieve rapid reduction symptoms, but significant work be done. Rigorous clinical trials combining outcomes neuroscientific measures such electroencephalogram, magnetic resonance imaging e-field modeling needed define future MDD.

Language: Английский

Citations

52
A Gpr35-tuned gut microbe-brain metabolic axis regulates depressive-like behavior DOI Creative Commons

Lingsha Cheng,

Haoqian Wu, Xiaoying Cai

et al.

Cell Host & Microbe, Journal Year: 2024, Volume and Issue: 32(2), P. 227 - 243.e6

Published: Jan. 9, 2024

Language: Английский

Citations

40
Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player? DOI Creative Commons

Mehdi Sekssaoui,

Joël Bockaert, Philippe Marin

et al.

Neuropsychopharmacology, Journal Year: 2024, Volume and Issue: 49(4), P. 747 - 756

Published: Jan. 11, 2024

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in world. First-line treatments such as selective serotonin reuptake inhibitors (SSRIs) still have many limitations, including a resistance to treatment 30% patients and delayed clinical benefit that observed only after several weeks treatment. Increasing evidence indicates acute administration psychedelic agonists 5-HT

Language: Английский

Citations

25
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile DOI Creative Commons
Friederike Holze, Nirmal Singh, Matthias E. Liechti

et al.

Biological Psychiatry Cognitive Neuroscience and Neuroimaging, Journal Year: 2024, Volume and Issue: 9(5), P. 472 - 489

Published: Feb. 1, 2024

Psychedelic compounds, including psilocybin, LSD, DMT, and 5-MeO-DMT all of which are serotonin (5-HT) 2A receptor agonists being investigated as potential treatments. This review aims to summarize the current clinical research on these four compounds mescaline guide future research. Their mechanism/s action, pharmacokinetics, pharmacodynamics, efficacy, safety were reviewed. While evidence for therapeutic indications, with exception psilocybin depression, is still relatively scarce, we noted no differences in psychedelic effects beyond effect duration. It remains therefore unclear whether different profiles contribute compounds. More needed differentiate order inform might be best uses.

Language: Английский

Citations

21
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects DOI Creative Commons
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer

et al.

Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 8, 2024

There is growing scientific evidence for the therapeutic benefits of Amazonian plant-based psychedelic "ayahuasca" neuropsychiatric disorders such as depression and anxiety. However, there are certain challenges when incorporating botanical ayahuasca into biomedical research clinical therapy environments. Formulations inspired by ayahuasca, which contain specific standardized active components, a potential remedy.

Language: Английский

Citations

17
CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity DOI
M. Madsen, Anja Sofie Petersen, Dea Siggaard Stenbæk

et al.

Headache The Journal of Head and Face Pain, Journal Year: 2024, Volume and Issue: 64(1), P. 55 - 67

Published: Jan. 1, 2024

Abstract Objective To evaluate the feasibility and prophylactic effect of psilocybin as well its effects on hypothalamic functional connectivity (FC) in patients with chronic cluster headache (CCH). Background CCH is an excruciating difficult‐to‐treat disorder incompletely understood pathophysiology, although dysfunction has been implicated. Psilocybin may have beneficial effects, but clinical evidence limited. Methods In this small open‐label trial, 10 were included maintained diaries for weeks. Patients received three doses peroral (0.14 mg/kg) first day weeks five, six, seven. The 4 served baseline last follow‐up. Hypothalamic FC was determined using magnetic resonance imaging before dose 1 week after dose. Results treatment tolerated. Attack frequency reduced by mean (standard deviation) 31% (31) from to follow‐up ( p FWER = 0.008). One patient experienced 21 complete remission. Changes hypothalamic–diencephalic correlated negatively a percent change attack 0.03, R −0.81), implicating neural pathway response. Conclusion Our results indicate that potential implicates hypothalamus possible Further studies are warranted.

Language: Английский

Citations

16
Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms DOI Creative Commons
Kyna‐Anne Conn, Laura K Milton, Kaixin Huang

et al.

Molecular Psychiatry, Journal Year: 2024, Volume and Issue: 29(10), P. 3291 - 3304

Published: April 27, 2024

Abstract Psilocybin has shown promise for alleviating symptoms of depression and is currently in clinical trials the treatment anorexia nervosa (AN), a condition that characterised by persistent cognitive inflexibility. Considering enhanced flexibility after psilocybin reported to occur individuals with depression, it plausible could improve AN breaking down A mechanistic understanding actions required tailor application most likely respond positive outcomes. This can only be achieved using incisive neurobiological approaches animal models. Here, we use activity-based (ABA) rat model comprehensively assess aspects reinforcement learning show (post-acutely) improves body weight maintenance female rats facilitates flexibility, specifically via improved adaptation initial reversal reward contingencies. Further, reveal involvement signalling through serotonin (5-HT) 1 5-HT2A receptor subtypes specific learning, demonstrating 5-HT1A antagonism negates enhancing effects psilocybin. Moreover, elicits transient increase decrease cortical transcription these receptors ( Htr2a Htr1a , respectively), further reduction abundance transcripts exposed ABA model. Together, findings support hypothesis ameliorate inflexibility context highlight need better understand therapeutic mechanisms independent binding.

Language: Английский

Citations

16
Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice DOI

Xiangting Zhao,

Yingjie Du, Yishan Yao

et al.

Journal of Psychopharmacology, Journal Year: 2024, Volume and Issue: 38(5), P. 489 - 499

Published: April 28, 2024

Background: Psilocybin offers new hope for treating mood disorders due to its rapid and sustained antidepressant effects, as standard medications require weeks or months exert their effects. However, the mechanisms underlying this action of psilocybin have not been identified. Aims: To investigate whether has antidepressant-like effects in mice potential are related promoted neuroplasticity. Methods: We first examined normal by forced swimming test chronic corticosterone (CORT)-exposed sucrose preference novelty-suppressed feeding test. Furthermore, explore role neuroplasticity mediating psilocybin, we measured structural neuroplasticity-associated protein levels prefrontal cortex (PFC) hippocampus. Results: observed that a single dose had both healthy CORT-exposed mice. Moreover, ameliorated CORT exposure-induced inhibition PFC hippocampus, including increasing (total number dendritic branches spine density), synaptic (p-GluA1, PSD95 synapsin-1) levels, BDNF-mTOR signalling pathway activation (BDNF, TrkB mTOR levels), promoting neurogenesis (number DCX-positive cells). Conclusions: Our results demonstrate elicits robust, which is accompanied promotion

Language: Английский

Citations

16
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications DOI Creative Commons
Francesco Weiss, Anna Magnesa,

Matteo Gambini

et al.

Brain Sciences, Journal Year: 2025, Volume and Issue: 15(2), P. 117 - 117

Published: Jan. 25, 2025

Background: Psychedelics are increasingly recognized as a promising and innovative treatment strategy for several mental disorders. However, there is still lively controversy in the medical community regards rationale of their employment, specifically indications potential dangers. Methods: A comprehensive literature search on “MEDLINE/PubMed” “Web Science” was performed from inception to 26 June 2024, cross-checking obtained references. We included all studies, i.e., both clinical preclinical, that supplied original data. Results: initially total 1083 entries, 813 MEDLINE/PubMed 270 Web Science. After duplicate elimination, 903 underwent systematic selection. Primary abstract screening yielded 572 candidates eligibility assessment excluded 331 entries formal grounds. Eligibility led exclusion 501 titles. Finally, 70 articles were this review. Discussion: Preclinical evidence genetic expression, histology behavioral studies soundly consistent with psychedelics possessing neuroplasticity-inducing properties. Despite methodological difficulties, seems be inferentially agreement preclinical findings. it unclear whether “neuroplastic boost” induced by classic might dissociable psychodysleptic effects, thereby reducing psychopathological hazards implied these compounds. Moreover, fact so-called “relaxation priors” should unconditionally beneficial appears debatable, further research clarify possible contraindications psychedelic psychoplastogens within precision medicine perspective.

Language: Английский

Citations

5